Bristol-Myers Shareholders Vote in Favor of $74 Billion Celgene Acquisition
April 12 2019 - 11:04AM
Dow Jones News
*** Bristol-Myers Shareholders Vote In Favor Of $74B Celgene
Acquisition
*** Bristol-Celgene Combination Creates Cancer Drug Powerhouse
With Nearly $38 billion in Yearly Sales
*** Bristol-Myers Approval For Celgene Follows Unsuccessful
Activist Campaign to Undo Deal
(END) Dow Jones Newswires
April 12, 2019 10:49 ET (14:49 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2024 to May 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From May 2023 to May 2024